BR0110971A - Composições e métodos para tratamento de infecções das mucosas - Google Patents

Composições e métodos para tratamento de infecções das mucosas

Info

Publication number
BR0110971A
BR0110971A BR0110971-5A BR0110971A BR0110971A BR 0110971 A BR0110971 A BR 0110971A BR 0110971 A BR0110971 A BR 0110971A BR 0110971 A BR0110971 A BR 0110971A
Authority
BR
Brazil
Prior art keywords
methods
compositions
infections
mucosal infections
treating mucosal
Prior art date
Application number
BR0110971-5A
Other languages
English (en)
Inventor
Robert Llewellyn Clancy
Gerald Pang
Margaret Lorraine Dunkleyy
Original Assignee
Pneumobiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pneumobiotics Pty Ltd filed Critical Pneumobiotics Pty Ltd
Publication of BR0110971A publication Critical patent/BR0110971A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA TRATAMENTO DE INFECçõES DAS MUCOSAS". A presente invenção refere-se a novas composições e vacinas úteis para tratamento profilático e/ou terapêutico de infecções nas mucosas, e, em particular, refere-se a vacinas orais e a métodos para intensificar a resistência das mucosas a infecções ou para tratar infecções estabelecidas, do trato respiratório.
BR0110971-5A 2000-05-19 2001-05-21 Composições e métodos para tratamento de infecções das mucosas BR0110971A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ7612A AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections
PCT/AU2001/000588 WO2001087332A1 (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections

Publications (1)

Publication Number Publication Date
BR0110971A true BR0110971A (pt) 2005-04-05

Family

ID=3821690

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110971-5A BR0110971A (pt) 2000-05-19 2001-05-21 Composições e métodos para tratamento de infecções das mucosas

Country Status (10)

Country Link
US (1) US8637051B2 (pt)
EP (1) EP1305042B1 (pt)
JP (2) JP5567756B2 (pt)
KR (1) KR20030019389A (pt)
CN (1) CN1437480A (pt)
AT (1) ATE535284T1 (pt)
AU (1) AUPQ761200A0 (pt)
BR (1) BR0110971A (pt)
CA (1) CA2409813C (pt)
WO (1) WO2001087332A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
US20080044440A1 (en) * 2004-02-18 2008-02-21 Margaret Dunkley Vaccine Formulated For Administration To Mucosa Of The Lungs
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US20070269376A1 (en) * 2004-08-17 2007-11-22 Hunter Immunology Limited Method for Determining Dosage for an Oral Killed Vaccine
WO2006017895A1 (en) * 2004-08-17 2006-02-23 Hunter Immunology Pty Limited Oral killed vaccines and method for providing same
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US8857659B2 (en) 2010-03-18 2014-10-14 Eveready Battery Company, Inc. Button cell battery dispenser package
WO2011161491A1 (en) * 2010-06-25 2011-12-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of respiratory tract infections
US20140275420A1 (en) 2011-08-22 2014-09-18 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
AU2015252726B2 (en) * 2014-05-02 2020-12-24 Qu Biologics Inc. Anti-microbial immunomodulation
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
JPH0680575A (ja) * 1991-03-05 1994-03-22 Meiji Milk Prod Co Ltd 経口免疫賦活剤
EP1649868A1 (en) * 1996-05-31 2006-04-26 National University of Ireland, Maynooth IL-12 as an adjuvant for Bordetella pertussis vaccines
EP0988053A1 (en) * 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
US6287568B1 (en) 1997-09-09 2001-09-11 The Trustees Of Columbia University In The City Of New York Methods relating to immunogenic dextran-protein conjugates
US6153182A (en) * 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
BR9814432A (pt) 1997-12-23 2000-10-10 Genesis Res & Dev Corp Ltd Composições derivadas de mycobacterium vaccae e processo para seu uso
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
HU228467B1 (en) 1998-02-05 2013-03-28 Smithkline Beecham Biolog Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
SE9800615D0 (sv) * 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
AU747917B2 (en) * 1998-03-05 2002-05-30 Medical College Of Ohio, The Enhancement of immunity by intranasal inoculation of IL-12
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
EP1087788A1 (fr) * 1998-06-26 2001-04-04 Aventis Pasteur Immunisation a ciblage mucosal
AR020102A1 (es) * 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
DE60142786D1 (de) * 2000-06-19 2010-09-23 Hunter Immunology Ltd Zusammensetzungen und methoden zur behandlung von candidosen
NZ536894A (en) * 2000-08-08 2006-04-28 Vialactia Bioscience Nz Ltd Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them

Also Published As

Publication number Publication date
EP1305042A4 (en) 2005-02-02
EP1305042A1 (en) 2003-05-02
EP1305042B1 (en) 2011-11-30
KR20030019389A (ko) 2003-03-06
CA2409813C (en) 2013-11-12
CA2409813A1 (en) 2001-11-22
JP5567756B2 (ja) 2014-08-06
ATE535284T1 (de) 2011-12-15
CN1437480A (zh) 2003-08-20
US8637051B2 (en) 2014-01-28
AUPQ761200A0 (en) 2000-06-15
JP2012153706A (ja) 2012-08-16
US20040057965A1 (en) 2004-03-25
JP2003533489A (ja) 2003-11-11
WO2001087332A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
BR0110971A (pt) Composições e métodos para tratamento de infecções das mucosas
BR0211049A (pt) Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae
NO2016006I1 (no) Prodroger av fosfonatnukleotidanaloger,preparat derav og dets anvendelse til terapeutisk og profylaktisk behandling av virusinfeksjoner
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
MXPA03005340A (es) Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida.
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
BR0113085A (pt) Composições que incluem bactérias que oxidam amÈnia para aumentar a produção de óxido nìtrico e precursores de óxido nìtrico, e métodos de uso dessas composições
BRPI0009163B8 (pt) composição imunogênica e vacina que a compreende
ATE335510T1 (de) Methoden und produkte zur induzierung mukosaler immunität
GB0025577D0 (en) Vaccine
BR0308051A (pt) Composição base para preparação de formulações multifuncionais para o cuidado e proteção da pele e cabelo
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
BR0114392A (pt) Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv
BRPI9700768B1 (pt) vacina viva para combater infecção por streptococcus em cavalos.
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE69826019D1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
BR0101486A (pt) Composições farmacêuticas de uso tópico, aplicadas no tratamento de lesões de pele e/ou mucosas; uso das composições no tratamento de lesões de pele e/ou mucosas e uso de compostos no tratamento de lesões de pele e/ou mucosas
BRPI0208411B8 (pt) composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto
HUP0301634A2 (hu) Hőmérséklet-érzékeny, élő vakcina Mycoplasma hyopneumoniaera
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
WO2001055111A8 (en) Biaryl compounds, their preparation and their use in therapy
BR0211563A (pt) Modelo de infecção por mycoplasma bovis e métodos para administração de m. bovis e para indução de lesões pneumÈnicas do pulmão
EA200100515A2 (ru) Диазепиноиндолы для лечения хронического обструктивного заболевания легких
MXPA03011622A (es) Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]